(Alliance News) - Haleon PLC is exploring a potential divestment of some smoking cessation products, including the Nicotinell brand of nicotine gum, patches and lozenges, according to a Bloomberg report on Tuesday. Read More
(Alliance News) - GSK PLC on Wednesday said it completed its acquisition of Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion. Read More
(Alliance News) - GSK PLC on Tuesday reported that the US Food & Drug Administration has granted its gonorrhoea investigational vaccine a "fast track" designation. Read More
(Alliance News) - Stock prices in London were set to open higher on Tuesday, following a positive session for equities in Hong Kong and Shanghai. Read More
(Alliance News) - GSK PLC on Monday celebrated several regulatory approvals for new drug therapies, including treatments for shingles. Read More
(Alliance News) - Stocks in London were set to start the new week marginally lower, with financial markets unfazed by a failed revolt by a mercenary army in Russia over the weekend. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Stocks in London closed lower on Friday as weak economic data and the prospect of global interests staying higher for longer put investors in a firmly risk-off mood. Read More
(Alliance News) - Stock prices in London were lower heading into Friday afternoon, as a poor week for equities continued, with investors fretting over the prospect of central banks keeping interest rates higher for longer. Read More
(Alliance News) - Stock prices in London opened lower on Friday, as rising interest rates weighed on housebuilding stocks in the FTSE 100. Read More
(Alliance News) - GSK PLC on Friday said a Zantac trial set to begin next month in California has been dismissed after it reached a confidential settlement. Read More
(Alliance News) - Stocks in London are set to open in the red on Friday, as risk sentiment across the globe is damped by hawkish central banks. Read More
(Alliance News) - GSK PLC on Thursday said the US Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices has voted to recommend the firm's Arexvy jab in adults aged 60 and older. Read More
(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults. Read More
(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks. Read More
(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday. Read More
GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review." Read More
(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab. Read More
(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended. Read More
(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite. Read More